[go: up one dir, main page]

PE20040168A1 - Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas - Google Patents

Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas

Info

Publication number
PE20040168A1
PE20040168A1 PE2003000316A PE2003000316A PE20040168A1 PE 20040168 A1 PE20040168 A1 PE 20040168A1 PE 2003000316 A PE2003000316 A PE 2003000316A PE 2003000316 A PE2003000316 A PE 2003000316A PE 20040168 A1 PE20040168 A1 PE 20040168A1
Authority
PE
Peru
Prior art keywords
hydrogen
cycloalkyl
alkyl
cyane
pyridazin
Prior art date
Application number
PE2003000316A
Other languages
English (en)
Inventor
Stephanie Barbosa
Mark E Salvati
John T Hunt
Zhong Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20040168A1 publication Critical patent/PE20040168A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE COMPUESTOS DE PIRROLOPIRIDAZINA DE FORMULA I DONDE R1 ES HIDROGENO, HIDROXILO, ALQUILO, HALOGENO ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO, HETEROCICLO, ENTRE OTROS; R1 Y R2 PUEDEN FORMAR UN CICLOALQUILO, ARILO, ENTRE OTROS; X ES UN ENLACE DE VALENCIA, O, S, ENTRE OTROS; R3 ES HIDROGENO, HIDROXILO, ALQUILO, CICLOALQUILO, HETROCICLO, ENTRE OTROS; R4 ES HIDROGENO, ALQUILO, ARILO, HETEROCICLO, ARALQUILO, ENTRE OTROS; Y ES UN ENLACE DE VALENCIA, O, S, ENTRE OTROS; R5 ES HIDROGENO, CIANO, HALOGENO, ENTRE OTROS; Z ES UN ENLACE DE VALENCIA, O, S, ENTRE OTROS; R6 ES HIDROGENO, CICLOALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS:ACIDO 3-CIANO-4-(CICLOHEXILAMINO)-5-METILPIRROLO[1,2-b]PIRIDAZIN-6-CARBOXILICO, ESTER ETILICO DE ACIDO 3-CIANO-5-METIL-4-FENOXIPIRROLO[1,2-b]PIRIDAZIN-6-CARBOXILICO,6-(METOXIMETIL)-5-METIL-4-[(4-FENOXIMETIL)AMINO]PIRROLO[1,2-b]PIRIDAZIN-3-CARBONITRILO, ACIDO4-[(2-CLORO-4-YODOFENIL)AMINO]-3-CIANO-5-METILPIRROLO[1,2-b]PIRIDAZIN-6-CARBOXILICO ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LAS PROTEINA CINASAS Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS PROLIFERATIVOS, INFLAMATORIOS
PE2003000316A 2002-03-28 2003-03-28 Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas PE20040168A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36824902P 2002-03-28 2002-03-28
US40211802P 2002-08-08 2002-08-08

Publications (1)

Publication Number Publication Date
PE20040168A1 true PE20040168A1 (es) 2004-03-27

Family

ID=28678223

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000316A PE20040168A1 (es) 2002-03-28 2003-03-28 Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas

Country Status (12)

Country Link
US (2) US6900208B2 (es)
EP (1) EP1578351B1 (es)
JP (1) JP4589005B2 (es)
AR (1) AR039189A1 (es)
AT (1) ATE490964T1 (es)
AU (1) AU2003223380A1 (es)
CL (1) CL2008003391A1 (es)
DE (1) DE60335293D1 (es)
PE (1) PE20040168A1 (es)
PL (1) PL374759A1 (es)
TW (1) TW200403245A (es)
WO (1) WO2003082208A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1581535B3 (en) 2003-01-09 2009-09-02 Astellas Pharma Inc. Pyrrolopyridazine derivatives
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
WO2007035428A1 (en) * 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007058392A1 (ja) * 2005-11-21 2007-05-24 Japan Tobacco Inc. ヘテロ環化合物およびその医薬用途
HRP20151398T1 (hr) 2006-12-22 2016-02-12 Astex Therapeutics Limited Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze
CN101679408B (zh) * 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
US8293897B2 (en) 2008-10-14 2012-10-23 Ning Xi Compounds comprising a spiro-ring and methods of use
RU2011142597A (ru) * 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. Производные сложных эфиров аминокислот, их соли и способы применения
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
AR077346A1 (es) * 2009-07-31 2011-08-17 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de janus quinasa
ES2616026T3 (es) * 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolopiridazinas como inhibidores de canales de iones potasio
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
EP3710005B8 (en) * 2017-11-17 2023-06-14 Academia Sinica SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER
IL279977B2 (en) 2018-07-09 2024-06-01 Boehringer Ingelheim Animal Health Usa Inc Heterocyclic anthelmintic compounds
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
IL312412A (en) 2021-11-01 2024-06-01 Boehringer Ingelheim Vetmedica Gmbh Pyrrolopyridazine compounds against worms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059999A1 (en) * 1998-05-21 1999-11-25 Shionogi & Co., Ltd. PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2 INHIBITORY EFFECT
BR9913654A (pt) 1998-08-28 2001-11-27 Scios Inc Inibidores de p-38alfa quinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
WO2002000621A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
GEP20063915B (en) 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
CL2008003391A1 (es) 2009-03-06
US6900208B2 (en) 2005-05-31
AU2003223380A8 (en) 2003-10-13
EP1578351B1 (en) 2010-12-08
AR039189A1 (es) 2005-02-09
AU2003223380A1 (en) 2003-10-13
WO2003082208A2 (en) 2003-10-09
EP1578351A4 (en) 2006-06-14
EP1578351A2 (en) 2005-09-28
US20040063712A1 (en) 2004-04-01
US20050159420A1 (en) 2005-07-21
ATE490964T1 (de) 2010-12-15
WO2003082208A3 (en) 2006-03-02
JP4589005B2 (ja) 2010-12-01
PL374759A1 (en) 2005-10-31
JP2006504624A (ja) 2006-02-09
DE60335293D1 (de) 2011-01-20
TW200403245A (en) 2004-03-01
WO2003082208A8 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
PE20040168A1 (es) Compuestos de pirrolopiridazina como inhibidores de las proteina cinasas
PE20080548A1 (es) Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de cinasa de proteina
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20091095A1 (es) Moduladores de gamma secretasa
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20030129A1 (es) Imidazotriazinas
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
AR029215A1 (es) Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20110102A1 (es) Derivados de n-(2-oxo-2-pirrolidinil-1-il)etil-2-amino-acetamida como inhibidores de proteinas de apoptosis (iap)
PE20040197A1 (es) Pirazolopiridinas sustituidas con carbamato
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20081370A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20091116A1 (es) Derivados de piridina y pirazina como inhibidores de tirosina quinasas
GT200300129A (es) Derivados de heteroarilamida benzo condensada de tienopiridinas utiles como agentes terapeuticos,composiciones farmaceuticas que incluyen a los mismos y metodo para su uso
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20010401A1 (es) DERIVADOS DE 8-FENIL-6,9-DIHIDRO-[1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA COMO INHIBIDORES DE FOSFODIESTERASA ESPECIFICA DE GMP CICLICO
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
PE20010543A1 (es) Derivados de purina como inhibidores de tirosincinasa syk

Legal Events

Date Code Title Description
FD Application declared void or lapsed